# Bactiguard Holding > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/bactiguardholdingb). ## Overview Bactiguard Holding AB is a global MedTech company based in Stockholm, Sweden, specializing in the development of biocompatible technology to prevent infections associated with medical devices. The company's proprietary technology involves an ultra-thin noble metal coating that reduces bacterial adhesion and biofilm formation. Bactiguard operates primarily through license partnerships with leading MedTech companies, allowing them to apply its infection prevention technology to their medical devices. The company also offers a portfolio of wound management products, contributing to its mission of reducing patient suffering and combating antimicrobial resistance. ## Products & services • Infection prevention technology for medical devices • Noble metal coating for bacterial adhesion reduction • License partnerships with MedTech companies • Wound management products • Hydrocyn aqua for wound care - **Infection Prevention Technology** (60%) — Technology to prevent infections on medical devices. - **License Partnerships** (30%) — Collaborations with MedTech companies to apply technology. - **Wound Management Products** (10%) — Products aimed at wound care and management. - Infection prevention technology for medical devices - Noble metal coating for bacterial adhesion reduction - License partnerships with MedTech companies - Wound management products - Hydrocyn aqua for wound care ## Customers Bactiguard's customers primarily include global MedTech companies that integrate its infection prevention technology into their medical devices. These companies benefit from enhanced device performance and reduced infection rates, which are critical in healthcare settings. Additionally, healthcare providers and institutions use Bactiguard's wound management products to improve patient outcomes and reduce healthcare costs. The company's focus on partnerships allows it to scale its technology across various medical applications and geographies. - **MedTech Companies** (primary) — Purchase technology for integration into medical devices. - **Healthcare Providers** (secondary) — Use wound management products to improve patient care. - **Institutional Buyers** (emerging) — Seek solutions to reduce healthcare costs and improve outcomes. - Global MedTech companies seeking infection prevention solutions - Healthcare providers aiming to reduce infection rates - Institutions looking to improve patient outcomes - Partners benefiting from enhanced device performance ## Geography Bactiguard is headquartered in Stockholm, Sweden, and operates globally through its partnerships with leading MedTech companies. The company’s technology is applied in various regions, enhancing its global presence. Bactiguard's strategic focus on partnerships allows it to penetrate diverse markets, including Europe, North America, and Asia. The company's geographic reach is critical for its growth strategy, enabling it to address infection prevention needs worldwide. - Headquartered in Stockholm, Sweden - Global operations through MedTech partnerships - Presence in Europe, North America, and Asia - Strategic focus on diverse market penetration ## Strategy Bactiguard's strategic priorities include expanding its license partnerships and increasing the application areas for its infection prevention technology. The company aims to achieve an EBITDA of SEK 200 million by 2030, driven by its scalable business model. Bactiguard is also focusing on enhancing its wound management portfolio, which has shown significant growth. These strategic initiatives are designed to strengthen its market position and address the growing demand for infection prevention solutions. - **Expand License Partnerships** (medium-term) — To increase market reach and application areas. - **Achieve SEK 200 million EBITDA** (long-term) — To ensure financial growth and stability. - **Enhance Wound Management Portfolio** (short-term) — To capture growth in wound care market. - Expand license partnerships and application areas - Achieve SEK 200 million EBITDA by 2030 - Enhance wound management portfolio - Strengthen market position in infection prevention ## Risks Bactiguard faces several risks, including dependency on key partnerships and regulatory challenges in different markets. The company's success is closely tied to its ability to maintain and expand its partnerships with MedTech companies. Regulatory approvals can be time-consuming and impact the commercialization of new applications. Additionally, the company is exposed to currency fluctuations due to its global operations. Industry-specific risks include the threat of antimicrobial resistance, which could affect the demand for infection prevention solutions. - **Dependency on Partnerships** [high] — Revenue heavily reliant on MedTech collaborations. - **Regulatory Challenges** [medium] — Delays in approvals can impact market entry. - **Currency Fluctuations** [medium] — Global operations expose to exchange rate risks. - Dependency on key partnerships for revenue - Regulatory challenges in market approvals - Exposure to currency fluctuations - Threat of antimicrobial resistance affecting demand ## Accounting Bactiguard's financial statements are prepared in accordance with IFRS, with a focus on revenue recognition and segment reporting. The company's revenue is primarily derived from license agreements, which require careful accounting for royalties and development fees. Currency fluctuations can affect reported revenues, necessitating adjustments for currency effects. The company also faces challenges in estimating provisions for inventory and receivables, impacting financial results. These accounting matters are critical for accurately assessing Bactiguard's financial performance. - **Revenue Recognition** — Significant on financial results - **Currency Fluctuations** — Material on financial statements - **Provisions for Inventory** — Critical for accurate assessment - Revenue recognition from license agreements - Impact of currency fluctuations on reported revenues - Provisions for inventory and receivables - IFRS compliance in financial reporting --- *Last updated: 2026-08-11T04:04:51.088498+00:00*